. >> jared holtz is telling me investors are keeping a closer eye on this for any similar commentary of tax benefits they are boosting gilead for their results for hepatitis "c" drugs. it says a 32% market share brian abrams calling this a positive indicator for market stabilization in terms of number of patients treated as well as pricing. all of this leading biotech to get seriously close to its 2015 high here is where the warnings start to come in damian is pointing out some of the activity in the space is causing investors to worry the sector is taking a turn for the absurd they point out the state of the union address next week. it could throw some cold water on the group in addition to pfizer and amgen reporting, wednesday will bring reports from eli lilly and v vertez >> dan had called it the best chart ever on ""fast money." >> i say on a relative basis it is very constructive. we are in a market that is seemingly making new all-time highs on a daily basis we have seen a lot of rotations, in some groups and out of others when you look at pickup we have seen in biotech, we hav